IntelGenx Provides Update on RIZAPORT® VersaFilm® NDA Resubmission Process Following Type A Meeting with the FDA

Stock Information for IntelGenx Technologies Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About IntelGenx Technologies Corp.

IntelGenx Announces First Parkinson's Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 'MONTPARK' Clinical Trial
IntelGenx Updates Status of Buprenorphine Buccal Film ANDA
IntelGenx Reports Fourth Quarter and Full-Year 2023 Financial Results
IntelGenx to Report Fourth Quarter and Full Year 2023 Financial Results on March 21, 2024 - Conference Call to Follow
IntelGenx Enters Into a Third Amended and Restated Loan Agreement With atai Life Sciences
UPDATE -- IntelGenx Launches Preferred Share Regulation A Offering
IntelGenx Launches Preferred Share Regulation A Offering
Studies Validate Advantages of Administering Drugs to Pets via IntelGenx's VetaFilm® Platform

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.